A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician?s Choice in Subjects with Fibroblast Growth Factor Receptor FGFR-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma FIRST-308

Brief Summary

Type:
Liver

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT05948475

Study #:
STUDY00160154

Start Date:
Apr 22, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05948475

View Complete Trial Details & Eligibility at ClinicalTrials.gov